Cancer cachexia is a major cause of morbidity and mortality, occurring in up to 80% of patients with advanced cancer and contributing directly to death in 20% of cases. Patients show profound wasting from both fat and skeletal muscle compartments with death usually occurring when weight loss reaches 30% of premorbid levels. The complex metabolic disturbances in cachexia result in a block in the accretion of lean body mass that nutritional supplementation and appetite stimulants alone are unable to reverse. This appears to be mediated through a combination of the proinflammatory cytokine response of the host, and the production of specific cytokines and catabolic factors by the tumour. The cytokines tumour necrosis factor α (TNF-α), interleukin 6 (IL-6), and interferon γ (IFN-γ) have all been implicated in the pathogenesis of cachexia, and in cachectic tumour bearing murine models treatment with anti-TNF-α, anti-IL-6, and anti-IFN-γ antibodies can attenuate the disease process. More recently, specific catabolic factors such as lipid mobilising factor and proteolysis inducing factor (PIF) which directly stimulate tissue breakdown have also been identified in cancer patients that are losing weight.

There is also some evidence that cytokines play a role in the pathogenesis of anorexia, which is commonly associated with cachexia. It has been suggested that by mimicking the hypothalamic effect of excessive negative feedback signalling from leptin by persistent stimulation of anorexigenic peptides such as corticotrophin releasing factor, or by inhibition of the neuropptide Y pathway, cytokines could induce anorexia. Thus modulating cytokine expression in cancer patients may also affect cancer associated anorexia.

Thalidomide has complex immunomodulatory and anti-inflammatory properties. It has been shown to downregulate the production of TNF-α and other proinflammatory cytokines, inhibit the transcription factor nuclear factor κB (NFκB), downregulate cyclooxygenase 2, and inhibit angiogenesis. In clinical trials it is effective in ameliorating human immunodeficiency virus associated wasting and the weight loss seen in subjects with active pulmonary tuberculosis. We therefore hypothesised that thalidomide would be effective in attenuating or reversing the weight loss seen in patients with cancer cachexia. During the course of our trial, an open label pilot study of thalidomide in the treatment of cachexia in 11 patients with inoperable oesophageal cancer has been reported. In this study, thalidomide reversed weight loss over the two weeks of the trial and this was associated with an increase in lean body mass. To date, no other trial evaluating the effect of thalidomide on cancer cachexia has been undertaken. Thus the aim of our present study was to assess the safety and efficacy of thalidomide in attenuating weight loss in patients with cachexia secondary to advanced pancreatic cancer.

**Patients and Methods**

**Patients**

Between April 1999 and April 2003, we undertook a prospective, randomised, double blind, placebo controlled study at a single centre (Queen Alexandra Hospital, Portsmouth, UK) in patients with cachexia due to inoperable pancreatic cancer. Inclusion criteria were: diagnosis of pancreatic cancer made on the basis of typical clinical and pathological features; proven weight loss of at least 10% of body weight over the two weeks prior to the trial; a Karnofsky performance status of ≥ 60; age over 18 years; and ongoing hormonal support for any endocrine tumour. Patients were excluded if they had undergone any previous cytotoxic chemotherapy, any other specific cytokine therapy, or any major surgery in the previous 3 months. Written informed consent was obtained from all patients. The study was approved by the South East MREC Committee.

**Methods**

Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial. The primary outcome was change in weight and nutritional status. Results: Thirty three patients (16 control, 17 thalidomide) were evaluated at four weeks, and 20 patients (eight control, 12 thalidomide) at eight weeks. At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm² in arm muscle mass (AMM) compared with a loss of 2.21 kg (absolute difference = 2.59 kg (95% confidence interval (CI) = 4.3 to −0.8; p = 0.005) and 4.46 cm² (absolute difference = 5.6 cm² (95% CI = −8.9 to −2.2; p = 0.002) in the placebo group. At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm² in AMM compared with a loss of 3.62 kg (absolute difference = 3.57 kg (95% CI = −6.8 to −0.3; p = 0.034) and 8.4 cm² (absolute difference = −7.9 cm² (95% CI = −14.0 to −1.8; p = 0.014) in the placebo group. Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).

**Conclusion:** Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
radiological findings, operative appearance, and/or histological diagnosis; patient deemed inoperable either on the basis of tumour anatomy, inability to survive major surgery, or patient preference; greater than 10% weight loss over the preceding six months; and likely life expectancy of at least six weeks based on clinical judgment. Exclusion criteria were: any form of treatment for pancreatic cancer in the preceding six weeks; weight less than 40 kg; concomitant use of corticosteroids, anabolic drugs, hormonal agents, or other appetite stimulants; age less than 18 years; subjective or objective evidence of peripheral neuropathy; severe constipation, vertigo, or vestibular disease; or severe comorbidity. Women of child bearing potential were required to have a negative pregnancy test prior to starting the trial and use two methods of contraception throughout the trial and for one month afterwards. The trial was approved by the local ethics committee and all patients gave written informed consent. All procedures were carried out in accordance with the declaration of Helsinki and the CONSORT guidelines.

Methods
At baseline, patients underwent a detailed medical history and examination. Premorbid weight and duration of weight loss were reported by the patient. Height (cm), weight (kg), mid upper arm circumference (MAC, cm), triceps skinfold thickness (TSF, mm), quality of life, full blood count, serum biochemistry, liver function tests, C reactive protein, and erythrocyte sedimentation rate were all recorded. All participants were weighed without shoes in their underclothes on the same set of spring balanced scales (SSEC, Germany). MAC was measured using stretch resistant tape and TSF the same set of spring balanced scales (SSEC, Germany). Grip strength was measured from the non-dominant hand using a digital hand grip dynamometer (Twinbird, Japan). Quality of life was determined using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 form, along with additional disease specific pancreatic cancer module PAN26.

Participants were subsequently assessed every four weeks for six months with the same measurements and blood tests recorded at each visit. All measurements were undertaken by the same investigator (TJ).

At enrolment, participants were randomised to receive either thalidomide 200 mg daily or identical placebo. Randomisation was undertaken in blocks of four using a sequential series of sealed envelopes containing a computer generated code. Randomisation envelopes were opened by a third party who dispensed the trial drug in a double blind fashion.

Thalidomide was obtained from Penn Pharmaceuticals Ltd (Gwent, UK) as 100 mg tablets, and prescribed in accordance with the published guidelines for the clinical use and dispensing of thalidomide. The dose of thalidomide was reduced to 100 mg in patients who suffered from unacceptable daytime somnolence, constipation, or developed a rash. Patients in whom symptoms did not subsequently resolve were then withdrawn from the trial. Compliance was assessed by participant self reporting and tablet count at each visit.

Outcome measures
The primary outcome measure was change in weight at four weeks. Secondary outcome measures were change in bone free muscle mass, grip strength, quality of life, and survival. Bone free arm muscle area (AMA), a validated marker of lean muscle mass, was calculated from MAC and TSF using the formula (MAC - πTSF^2)/4π minus a correction factor of 10 for male sex or 6.5 for female sex.

Adverse event information was obtained at every clinic visit by recording spontaneously reported complaints from patients and by asking specifically about recognised side effects.

Statistical analysis
Analysis was performed on an intention to treat basis. Data are presented as means (SEM) and absolute differences (95% confidence limits (CI)) when appropriate. Continuous variables were analysed using a two sample t test, Mann-Whitney U test, or the Pearson correlation test, as appropriate. Categorical data was analysed using Fisher’s exact test as appropriate. Survival curves were plotted using Kaplan-Meier survival estimates from the date of study enrolment. Results were considered statistically significant if the p value was less than 0.05.

Sample size calculations were undertaken based on assumptions from published studies of weight loss in patients with cancer cachexia. To detect a mean difference in weight of 2.5 kg at four weeks with 80% power and a 5% significance level, 17 patients were required in each group. This was inflated to 23 in each group to account for an attrition rate of 25% at four weeks.

Statistical calculations were performed using SPSS version 11.5 software (SPSS, Chicago, USA).

Table 1 Baseline patient characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Placebo group (n = 24)</th>
<th>Thalidomide group (n = 23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M:F)</td>
<td>13:11</td>
<td>12:11</td>
</tr>
<tr>
<td>Age (y)</td>
<td>71(1.7)</td>
<td>69(1.3)</td>
</tr>
<tr>
<td>Premorbid weight (kg)</td>
<td>73.0 (2.3)</td>
<td>77.1 (3.3)</td>
</tr>
<tr>
<td>Baseline weight (kg)</td>
<td>63.3 (2.2)</td>
<td>67.4 (2.7)</td>
</tr>
<tr>
<td>% Weight loss at baseline</td>
<td>13.2 (1.4)</td>
<td>12.1 (1.3)</td>
</tr>
<tr>
<td>Baseline MAC (mm)</td>
<td>27.1 (0.9)</td>
<td>27.6 (1.0)</td>
</tr>
<tr>
<td>Baseline Hb (g/dl)</td>
<td>12.1 (0.4)</td>
<td>12.4 (0.3)</td>
</tr>
<tr>
<td>Baseline Alb (g/dl)</td>
<td>35.0 (1.0)</td>
<td>37.1 (0.9)</td>
</tr>
<tr>
<td>Baseline ESR (mm/h)</td>
<td>62.0 (7.9) (n = 22)</td>
<td>54.7 (6.7) (n = 20)</td>
</tr>
<tr>
<td>Baseline C reactive protein (mg/l)</td>
<td>21.5 (4.8) (n = 22)</td>
<td>20.0 (9.5) (n = 22)</td>
</tr>
<tr>
<td>EORTC QLQ-C30 global health score*</td>
<td>50 (4.6)</td>
<td>56 (4.7)</td>
</tr>
<tr>
<td>EORTC QLQ-C30 physical functioning*</td>
<td>72 (5.1)</td>
<td>75 (5.1)</td>
</tr>
</tbody>
</table>

Values are mean (SEM). MAC, mean arm circumference; Hb, haemoglobin; Alb, albumin; ESR, erythrocyte sedimentation rate.
*EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire. High score represents high level of functioning (range 0–100).

There were no significant differences between the two groups.
RESULTS
A total of 50 patients were randomised and enrolled into the study. One subject in the placebo arm and two in the thalidomide arm were wrongly diagnosed and subsequently excluded from further analysis. Both patient groups were well matched at baseline with no significant difference between any of the variables \((p > 0.05)\) (table 1). Concomitant drug use was similar between the two groups: in the placebo group, 4/24 patients were taking Creon, 2/24 cholestyramine, 9/24 opiate analgesics, 7/24 other analgesics, 4/24 antidepressants, 8/24 cardiovascular medications, and 4/24 acid suppressants compared with 5/23, 3/23, 7/23, 10/23, 6/23, 11/23, and 6/23, respectively, in the treatment group. Patients were also well matched for global health score and physical functioning, as measured by the EORTC QLQ-C30 questionnaire. There were 33 patients available for assessment at four weeks and 20 at eight weeks. The predominant reason from withdrawal from the trial was death or disease progression (fig 1). The high attrition rate meant that after eight weeks there were too few patients for meaningful comparison.

Weight and nutritional status
At the primary end point of four weeks there was a significant difference in weight change, with patients in the treatment group gaining a mean of 0.37 kg while those in the placebo group lost a mean of 2.21 kg \((\Delta \text{weight} = -2.59 \text{ kg}; \ p = 0.005)\). At week 8 there was still a significant difference between the two groups, with patients in the treatment group losing 0.06 kg compared with 3.62 kg \((\Delta \text{weight} = -3.57 \text{ kg}; \ p = 0.034)\) in the placebo group (fig 2).

Figure 2 Change in weight in pancreatic cancer patients randomised to either thalidomide \((n = 17, \text{ week 4}; n = 12, \text{ week 8})\) or placebo \((n = 16, \text{ week 4}; n = 8, \text{ week 8})\). Differences between groups: \(p = 0.005\) at four weeks and \(p = 0.034\) at eight weeks.

Figure 3 Change in bone free arm muscle area (AMA) in pancreatic cancer patients randomised to either thalidomide \((n = 17, \text{ week 4}; n = 12, \text{ week 8})\) or placebo \((n = 16, \text{ week 4}; n = 8, \text{ week 8})\). Differences between groups: \(p = 0.002\) at four weeks and \(0.014\) at eight weeks.
At week 4 there was a significant difference in change in bone free AMA between the two groups. Patients in the treatment group had gained an average of 1 cm³ in bone free AMA while those in the placebo group lost an average of 4.6 cm³ (absolute difference –5.6 cm³ (–8.9 to –2.2); p = 0.002). This remained significant at week 8, with patients in the treatment group having lost an average of 0.5 cm³ compared with 8.4 cm³ (absolute difference –7.9 cm³ (–14.0 to –1.8); p = 0.014) in the placebo group (fig 3).

There was no significant difference in grip strength between the two groups at any time point. Additionally, grip strength did not differ significantly from baseline at any time in either group (table 2).

Quality of life measurements
There was no significant difference in global health score or physical functioning between the two groups or from baseline in either group. However, change in physical functioning correlated positively with change in weight (r = 0.56, p = 0.001) and there was a trend suggesting change in global health score correlated positively with change in weight, although this was not significant (r = 0.22, p = 0.221) (figs 4, 5).

Survival
Median duration of survival from entering the study was 148 days in the thalidomide group (95% CI 67–171) compared with 110 days in the placebo group (95% CI 75–136) although this was not statistically significant (p = 0.45). Kaplan-Meier survival curves were not significantly different between the two groups (fig 6).

Safety
Overall, thalidomide appeared to be well tolerated in this study. Two patients (9%) complained of peripheral neuropathy which resolved on stopping the drug, and two patients (9%) developed a rash that necessitated withdrawing from the trial. A further four patients (17%) complained of severe daytime somnolence that required a reduction in drug dosage in two patients and cessation of the drug in the other two. In the symptom scales at four weeks, constipation was significantly more common in the thalidomide group compared with placebo (p = 0.04) and insomnia significantly less common (p = 0.023). There was no significant difference between the two groups in any of the other symptom scales (fatigue, pain, nausea and vomiting, dyspnoea, appetite loss, diarrhoea, or financial difficulties). Other side effects were mild and did not differ significantly from placebo. Two patients in the placebo group and one in the thalidomide group developed deep vein thrombosis and were withdrawn from the study. Thalidomide has previously been associated with an increased risk of thromboembolism in patients with
malignant disease although this finding was not confirmed in the study.

**DISCUSSION**

Our study has shown that thalidomide attenuates weight loss in patients with cachexia secondary to pancreatic cancer and that this is associated with a reduction in loss of lean body mass. This is a clinically important finding as it has previously been shown that patients with unresectable pancreatic cancer show inexorable weight loss, as seen in our placebo group, with death occurring when patients have lost approximately 30% of their premorbid weight. However, our trial does have some potential limitations. Analysis and interpretation of results from studies involving patients with advanced cancer can be difficult due to the high attrition rate and resultant changing patient population. In our study, only 70% of patients were available for analysis at four weeks and 43% at eight weeks, raising the question that bias may have arisen due to selective attrition as the numbers in both groups were relatively small. Patients in the placebo arm were also on average 4 kg lighter than in the treatment arm, and although this difference was not significant it is possible that this could have contributed to differential weight loss between the two groups. However, the two groups were otherwise well matched for percentage weight loss, performance status, and inflammatory markers at the start of the trial, and the subsequent attrition rate and rate of weight loss in the placebo group was similar to that reported in previous studies, leading us to feel this was unlikely. Lean body mass was estimated indirectly using anthropometric measures which, although they have been shown to correlate well with other indirect measures of lean body mass, two large multicentre trials have recently failed to demonstrate any beneficial effect of EPA over either oral high calorie supplements or megestrol acetate. The only controlled trial to demonstrate an increase in lean body mass to date used a nutritional supplement containing the three amino acid related nutrients glutamine, arginine, and β-hydroxy-β-methylbutyrate. However, at four weeks total weight change was not significantly different between the two groups and lean body mass was only significantly different when measured by bioelectrical impedance analysis and not when measured by air displacement plethysmography.

Although the mechanism by which thalidomide attenuates weight loss is unknown it is likely that it results from modulation of the inflammatory response. One possibility is that its predominant effect is through downregulation of proinflammatory cytokines such as TNF-α. However, in the only previous randomised controlled trial of anti-TNF-α therapy in cachexia, pentoxifylline, a phosphodiesterase inhibitor which inhibits TNF-α production from macrophages, did not promote weight gain. In this respect it is interesting that pentoxifylline has also been found to be ineffective in the treatment of Crohn’s disease where TNF-α is known to play a central role. These disparate results may be explained by the fact that pentoxifylline is a rather poor inhibitor of TNF-α production compared with thalidomide.

Alternatively, there are several other possible mechanisms through which thalidomide may modulate the immune response in patients with cachexia. Thalidomide has been shown to inhibit NFκB, a ubiquitous intracellular signalling molecule involved in the transcriptional regulation of proinflammatory cytokines. NFκB controls both TNF-α and PIF-induced protein catabolism through upregulating the ubiquitin-proteasome pathway. Thalidomide can inhibit NFκB activity by suppressing inhibitor κB (IκB) kinase activity, inhibiting IκB degradation, and thus NFκB nuclear translocation. This may therefore represent a pathway through which thalidomide can downregulate both the proinflammatory host immune response and the activity of tumour derived catabolic factors. Thalidomide has also recently been shown to inhibit lipo polysaccharide mediated induction of cyclooxygenase 2 and prostaglandin E2 which may represent an alternative pathway by which it can promote an anti-inflammatory response. It is also feasible that thalidomide could directly affect cancer associated anorexia, in which cytokines are thought to play a key role, and thus influence the development of cachexia. However, in our study we did not find any significant difference in loss of appetite symptom scores between the thalidomide and placebo groups. Finally, it is possible that thalidomide has a direct effect on the pancreatic cancer itself as it has previously been shown to be active against a wide range of blood and solid organ malignancies.

In addition to the immunomodulatory effects of thalidomide, other properties may play a beneficial role in alleviating symptoms in patients with end stage cancer. In an uncontrolled study involving 37 patients with terminal disease...
malignancy, the antiemetic, analgesic, and sedative properties of thalidomide were shown to be effective in the palliation of otherwise intractable symptoms.\textsuperscript{43} In conclusion, we have demonstrated that thalidomide is safe and effective in attenuating severe weight loss in patients with advanced pancreatic cancer, and that this is associated with a reduction in loss of lean body mass. It remains to be seen whether these results can be generalised to all cancers and whether attenuation of weight loss leads to prolonged survival. In the future, combination of thalidomide with nutritional supplements and pharmacological agents may ultimately lead to a better clinical outcome.

**ACKNOWLEDGEMENTS**

We thank Mr Bernie Higgins (Senior Lecturer, Department of Gastroenterology, Queen Alexandra Hospital, Portsmouth, UK) for his help and advice with statistical analysis.

**Authors’ affiliations**

J N Gordon, T M Treble, R D Ellis, H D Duncan, T Johns, P M Goggin, Department of Gastroenterology, Queen Alexandra Hospital, Portsmouth, UK

Conflict of interest: None declared.

**REFERENCES**

38. Li YP, Reid MB. NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 2000;279:E162–70.

www.gutjnl.com